Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We reviewed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Whitney E. Lewis, PharmD, Lingzhi Hong, MD, PhD, Frank E. Mott, MD, George Simon, MD, Carol C. Wu, MD, Waree Rinsurongkawong, MS, MS, PhD, J. Jack Lee, MS, PhD, Vincent K. Lam, MD, John V. Heymach, MD, PhD, Jianjun Zhang, MD, PhD, Xiuning Le, MD, PhD
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Lung squamous cell carcinoma
Targeted therapy
Tyrosine kinase inhibitor
EGFR
ALK
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/2660592405ef472eb275c6fe7d53fee6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2660592405ef472eb275c6fe7d53fee6

Ejemplares similares